Names and pronunciation
(tam-sue-lo′sen) Flomax
Source page 1257
Loading InternPractice…
Individual generic drug information
Extracted information for tamsulosin only.
(tam-sue-lo′sen) Flomax
Source page 1257
Func. class.: Selective α1-peripheral adrenergic blocker, BPH agent
Source page 1257
Chem. class.: Sulfamoylphenethyl- amine derivative
Source page 1257
Do not confuse: Flomax/fosamax Tamsulosin/tacrolimus/tamoxifen
Source page 1257
ACTION: Binds preferentially to α1A- adrenoceptor subtype, which is located mainly in the prostate
Source page 1257
USES: Symptoms of benign prostatic hyperplasia (BPH) Unlabeled Uses: Ureteral stones as adjunctive treatment
Source page 1257
Extracted information for tamsulosin only.
CONTRAINDICATIONS: Hyper- sensitivity Precautions: Pregnancy, breastfeeding, children, hepatic disease, CAD, severe renal disease, prostate cancer; cataract surgery (floppy iris syndrome) T
Source page 1257
SIDE EFFECTS CNS: Dizziness, headache, asthenia, insomnia CV: Chest pain, orthostatic hypotension EENT: Amblyopia, floppy iris syndrome GI: Nausea, diarrhea, dysgeusia GU: Decreased libido, abnormal ejacula- tion, priapism INTEG: Rash, pruritus, urticaria MS: Back pain RESP: Rhinitis, pharyngitis, cough SYST: Angioedema
Source page 1258
INTERACTIONS Increase: B/P—prazosin, terazosin, doxazosin, α-blockers, vardenafil Increase: toxicity—cimetidine
Source page 1258
Extracted information for tamsulosin only.
DOSAGE AND ROUTES BPH • Adult: PO 0.4 mg/day increasing to 0.8 mg/day if required after 2-4 wk Ureteral stones (unlabeled) • Adult: PO 0.4 mg daily at bedtime up to 6 wk or expulsion of stones
Source page 1257
Available forms: Caps 0.4 mg
Source page 1257
Administer: • Without regard to food • Swallow caps whole; do not break, crush, or chew • Give 1⁄2 hr after same meal each day • If treatment is interrupted for several days, restart at lowest dose (0.4 mg/day) • Store in tight container in cool envi- ronment
Source pages 1257, 1258
Extracted information for tamsulosin only.
Assess: • Prostatic hyperplasia: change in uri- nary patterns at baseline and throughout treatment; I&O ratios, weight daily; edema; report weight gain or edema • Orthostatic hypotension: monitor B/P, standing, sitting, significant fall in B/P may occur • Pregnancy/breastfeeding: not to be used for women
Source page 1258
Evaluate: • Therapeutic response: decreased symptoms of benign prostatic hyperplasia
Source page 1258
CLINICAL CONSIDERATIONS
Source page 1258
Patient and caregiver information: • Not to drive or operate machinery for 4 hr after 1st dose or after dosage increase • To continue to take even if feeling better • To advise providers of all products, herbs taken • To make position changes slowly be- cause orthostatic hypotension may occur • To take 1⁄2 hr after same meal each day • To teach about priapism (rare) • Not to crush, break, chew • That decreased ejaculate or absence may occur; resolves after discontinuing product HIGH ALERT
Source page 1258
Extracted information for tamsulosin only.
PHARMACOKINETICS Peak 4-5 hr, duration 9-15 hr, half-life 9-13 hr, metabolized in liver, excreted via urine, extensively protein bound (98%)
Source page 1258
Filter the extracted dose blocks for this individual drug.
BPH
• Adult: PO 0.4 mg/day increasing to 0.8 mg/day if required after 2-4 wk Ureteral stones (unlabeled)
Candidate age grouping · source page 1257
BPH
• Adult: PO 0.4 mg daily at bedtime up to 6 wk or expulsion of stones
Candidate age grouping · source page 1257